Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bachem Holding AG's gross profit for the
six
months ended in Jun. 2026 was $102.2 Mil. Bachem Holding AG's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was $239.8 Mil.
Bachem Holding AG (OTCPK:BCHMF) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Bachem Holding AG had a gross margin of 25.01% for the quarter that ended in Jun. 2026 => Competition eroding margins
Bachem Holding AG Gross Profit Related Terms
Bachem Holding AG Gross Profit Historical Data
* Premium members only.
The historical data trend for Bachem Holding AG's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCHMF vs VRTX, REGN, RVMD: Gross Profit Comparison
For the Biotechnology subindustry, Bachem Holding AG's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bachem Holding AG Gross Profit vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bachem Holding AG's Gross Profit distribution charts can be found below:
* The bar in red indicates where Bachem Holding AG's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $239.8 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Bachem Holding AG (BCHMF) has a Gross Profit of $239.8 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Bachem Holding AG and its competitors.
Is Bachem Holding AG's Gross Profit too high?
Bachem Holding AG's current Gross Profit is $239.8 Mil. Overall, Bachem Holding AG has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bachem Holding AG's Gross Profit compare to VRTX and REGN?
Bachem Holding AG's Gross Profit of $239.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Bachem Holding AG and its competitors. Bachem Holding AG's current Gross Profit is $239.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bachem Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Bachem Holding AG (BCHMF) is currently considered Fairly Valued. The stock's GF Value™ is $93.72, compared to a current price of $91.00 — trading 2.9% below its estimated fair value. The current Gross Profit is $239.8 Mil. Bachem Holding AG's overall GF Score™ is 91/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Bachem Holding AG (BCHMF), the current Gross Profit is $239.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bachem Holding AG (BCHMF) Overvalued in 2026?
Based on GuruFocus' analysis, Bachem Holding AG stock appears to be undervalued.
The current stock price of $91.00 is trading 2.9% below its estimated GF Value™ of $93.72.
GuruFocus considers Bachem Holding AG to be Fairly Valued.
Key valuation signals for BCHMF:
Gross Profit: $239.8 Mil
GF Value™: $93.72 vs. price of $91.00 (2.9% below fair value)
No single metric tells the full story. See the BCHMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities. Geographically, it operates in Switzerland, USA, Ireland, Denmark, United Kingdom, and Rest of the World.
91GF Score
Get the complete analysis for BCHMF
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCHMF has been successfully added to your 
